<DOC>
	<DOCNO>NCT02194218</DOCNO>
	<brief_summary>Study determine pharmacokinetic property 200 mg nevirapine ( NVP ) administer 4 x 50 mg extend release ( XR ) tablets single dose establish bioequivalence formulation compare 200 mg NVP administer 2 x 100 mg XR tablet single dose</brief_summary>
	<brief_title>Pharmacokinetic Properties Nevirapine Extended Release Tablets When Administered Orally Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Healthy male accord follow criterion base upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory ; value within normal range deviate normal without clinical relevance consider investigator Age ≥21 Age ≤50 year Body Mass Index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 Signed date write informed consent prior admission study accordance Good clinical practice ( GCP ) local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder clinical relevance Surgery gastrointestinal tract ( except appendectomy herniotomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Previous intake Nevirapine Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 30 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>